AI Health & Biotechnology

Insilico Medicine Launches AI-Driven Longevity Board

Chaired by Eli Lilly's Andrew Adams, the new group will oversee AI research into biological aging processes.

By Kronos News Desk·April 21, 2026·1 min read

A high-tech laboratory environment featuring screens with DNA sequences and digital AI neural networks.
Photo: Kronos News

Insilico Medicine, a biotechnology firm, has launched a strategic Longevity Board to oversee its aging research ^[1]. The company describes the group as the first of its kind within the generative AI sector ^[1]. This board provides scientific guidance for discovering new therapeutics that target the biological mechanisms of aging ^[1].

Andrew Adams of Eli Lilly chairs the initiative, leading a team focused on AI-enabled drug discovery ^[1]. The board aims to accelerate the development of treatments meant to extend healthy lifespans ^[1]. This move signals a growing intersection between clinical-stage AI technology and longevity science ^[1].

Editorial notes

Transparency note

AI assisted drafting. Human edited and reviewed.

AI assisted: Yes
Human review: Yes
Last updated: April 21, 2026

Risk assessment

High

Risk level escalated to high due to single-source availability; the story relies entirely on a press release from one publisher, failing the internal requirement for three independent domains.